BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed SNY catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:604e4bf714d2a397e82b@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261125
DTEND;VALUE=DATE:20261126
SUMMARY:SNY P3 readout (est.): Rilzabrutinib for the Adult Participants Wit
 h Chronic ITP Who Have Completed Phase 3 Study in Japan
DESCRIPTION:Rilzabrutinib for the Adult Participants With Chronic ITP Who H
 ave Completed Phase 3 Study in Japan\nNCT07216079 | PHASE3 | ACTIVE_NOT_RE
 CRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line
  results usually follow later.\nTicker SNY (confidence 0.9)\nSource: https
 ://clinicaltrials.gov/study/NCT07216079\nScheduling/reference data from pu
 blic records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07216079
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:d8be294892c00b45b0fb@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261128
DTEND;VALUE=DATE:20261129
SUMMARY:SNY P3 readout (est.): A Phase III Control Study of the Safety and 
 Immunogenicity of vYF in Pediatric Population
DESCRIPTION:A Phase III Control Study of the Safety and Immunogenicity of v
 YF in Pediatric Population\nNCT07103148 | PHASE3 | ACTIVE_NOT_RECRUITING |
  sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line results u
 sually follow later.\nTicker SNY (confidence 0.9)\nSource: https://clinica
 ltrials.gov/study/NCT07103148\nScheduling/reference data from public recor
 ds\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07103148
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:cb1838763378c489d340@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SNY P3 readout (est.): Study of the Safety and Immunogenicity of Ca
 tch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21)
  in Healthy Infants\, Toddlers\, Children\, and Adolescents
DESCRIPTION:Study of the Safety and Immunogenicity of Catch-up Vaccination 
 With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants
 \, Toddlers\, Children\, and Adolescents\nNCT06838000 | PHASE3 | ACTIVE_NO
 T_RECRUITING | sponsor: Sanofi Pasteur\, a Sanofi Company\nPrimary complet
 ion date (ESTIMATED)\; top-line results usually follow later.\nTicker SNY 
 (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT06838000\nSc
 heduling/reference data from public records\; dates can move. Not investme
 nt\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06838000
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:2148e4c16fa472142ead@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:SNY P1/P2 readout (est.): Study to Evaluate the Safety and the Immu
 nogenicity of a Second Generation Structurally Designed mRNA Vaccine Candi
 date Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants
  Aged 18 Years and Older
DESCRIPTION:Study to Evaluate the Safety and the Immunogenicity of a Second
  Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic 
 Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Old
 er\nNCT06907511 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | sponsor: Sanofi\
 nPrimary completion date (ESTIMATED)\; top-line results usually follow lat
 er.\nTicker SNY (confidence 0.9)\nSource: https://clinicaltrials.gov/study
 /NCT06907511\nScheduling/reference data from public records\; dates can mo
 ve. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06907511
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:e92f658ad985b591ee00@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SNY P2 readout (est.): CHROMA CD
DESCRIPTION:A Study to Investigate Efficacy and Safety of Brivekimig in Par
 ticipants With Crohn's Disease\nNCT06958536 | PHASE2 | RECRUITING | sponso
 r: Sanofi\nPrimary completion date (ESTIMATED)\; top-line results usually 
 follow later.\nTicker SNY (confidence 0.9)\nSource: https://clinicaltrials
 .gov/study/NCT06958536\nScheduling/reference data from public records\; da
 tes can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06958536
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:c5d8b40d2db2836e7ab2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261217
DTEND;VALUE=DATE:20261218
SUMMARY:SNY P2 readout (est.): COLOR UC
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Brivekimig in
  Adult Participants With Ulcerative Colitis\nNCT06975722 | PHASE2 | ACTIVE
 _NOT_RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; t
 op-line results usually follow later.\nTicker SNY (confidence 0.9)\nSource
 : https://clinicaltrials.gov/study/NCT06975722\nScheduling/reference data 
 from public records\; dates can move. Not investment\, legal or medical ad
 vice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06975722
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:0837292088d2a5268f7a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261223
DTEND;VALUE=DATE:20261224
SUMMARY:SNY P2 readout (est.): RESULT
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Frexalimab\, Bri
 vekimig\, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primar
 y Focal Segmental Glomerulosclerosis or Minimal Change Disease\nNCT0650070
 2 | PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMA
 TED)\; top-line results usually follow later.\nTicker SNY (confidence 0.9)
 \nSource: https://clinicaltrials.gov/study/NCT06500702\nScheduling/referen
 ce data from public records\; dates can move. Not investment\, legal or me
 dical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06500702
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:6c28a105bc902b367217@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270107
DTEND;VALUE=DATE:20270108
SUMMARY:SNY P3 readout (est.): Study of a Single Dose of a 21-valent Pneumo
 coccal Conjugate Vaccine in Children and Adolescents With Sickle Cell Dise
 ase
DESCRIPTION:Study of a Single Dose of a 21-valent Pneumococcal Conjugate Va
 ccine in Children and Adolescents With Sickle Cell Disease\nNCT07247188 | 
 PHASE3 | RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)
 \; top-line results usually follow later.\nTicker SNY (confidence 0.9)\nSo
 urce: https://clinicaltrials.gov/study/NCT07247188\nScheduling/reference d
 ata from public records\; dates can move. Not investment\, legal or medica
 l advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07247188
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:612a064f24bcf2e0bafa@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270118
DTEND;VALUE=DATE:20270119
SUMMARY:SNY P1/P2 readout (est.): Study of a Human Metapneumovirus/Respirat
 ory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanopar
 ticle-based Formulation in Adults Aged 60 Years and Older
DESCRIPTION:Study of a Human Metapneumovirus/Respiratory Syncytial Virus mR
 NA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulatio
 n in Adults Aged 60 Years and Older\nNCT06686654 | PHASE1/PHASE2 | ACTIVE_
 NOT_RECRUITING | sponsor: Sanofi Pasteur\, a Sanofi Company\nPrimary compl
 etion date (ESTIMATED)\; top-line results usually follow later.\nTicker SN
 Y (confidence 0.6)\nSource: https://clinicaltrials.gov/study/NCT06686654\n
 Scheduling/reference data from public records\; dates can move. Not invest
 ment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06686654
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:031dd87b97a6dad3298a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270119
DTEND;VALUE=DATE:20270120
SUMMARY:SNY P1/P2 readout (est.): A First-in-human\, Dose Escalation and Do
 se Expansion Study of SAR445877 in Adult Participants With Advanced Solid 
 Tumors
DESCRIPTION:A First-in-human\, Dose Escalation and Dose Expansion Study of 
 SAR445877 in Adult Participants With Advanced Solid Tumors\nNCT05584670 | 
 PHASE1/PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary completion date (EST
 IMATED)\; top-line results usually follow later.\nTicker SNY (confidence 0
 .9)\nSource: https://clinicaltrials.gov/study/NCT05584670\nScheduling/refe
 rence data from public records\; dates can move. Not investment\, legal or
  medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT05584670
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:eee39d78132f5a0ff5a6@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270209
DTEND;VALUE=DATE:20270210
SUMMARY:SNY P2 readout (est.): BRIGHTEN
DESCRIPTION:Brivekimig for the Treatment of Moderate to Severe Hidradenitis
  Suppurativa\nNCT07170917 | PHASE2 | RECRUITING | sponsor: Sanofi\nPrimary
  completion date (ESTIMATED)\; top-line results usually follow later.\nTic
 ker SNY (confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT0717
 0917\nScheduling/reference data from public records\; dates can move. Not 
 investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07170917
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:33e9b61fda0e4a12418d@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:SNY P2 readout (est.): A Study to Investigate the Efficacy and Safe
 ty of Rilzabrutinib in Adult Participants With Graves' Disease
DESCRIPTION:A Study to Investigate the Efficacy and Safety of Rilzabrutinib
  in Adult Participants With Graves' Disease\nNCT06984627 | PHASE2 | RECRUI
 TING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-line res
 ults usually follow later.\nTicker SNY (confidence 0.9)\nSource: https://c
 linicaltrials.gov/study/NCT06984627\nScheduling/reference data from public
  records\; dates can move. Not investment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06984627
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:ece23fd306cbd2d851de@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:SNY P3 readout (est.): CEREN-3
DESCRIPTION:An Extension Study to Investigate the Long-term Safety and Tole
 rability of Itepekimab in Adult Participants With Inadequately Controlled 
 Chronic Rhinosinusitis With Nasal Polyps\nNCT07424144 | PHASE3 | ACTIVE_NO
 T_RECRUITING | sponsor: Sanofi\nPrimary completion date (ESTIMATED)\; top-
 line results usually follow later.\nTicker SNY (confidence 0.9)\nSource: h
 ttps://clinicaltrials.gov/study/NCT07424144\nScheduling/reference data fro
 m public records\; dates can move. Not investment\, legal or medical advic
 e.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT07424144
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:abd8e578e95d7da066c2@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20260709
DTEND;VALUE=DATE:20260710
SUMMARY:SNY APPROVAL: SARCLISA ESCENA
DESCRIPTION:Approved 2026-07-09: SARCLISA ESCENA (BLA761445 ORIG1)\nConfide
 nce: confirmed\nTicker SNY (confidence 0.6)\nSource: https://www.accessdat
 a.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761445\
 nScheduling/reference data from public records\; dates can move. Not inves
 tment\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overvie
 w.process&ApplNo=761445
CATEGORIES:approval,confirmed
END:VEVENT
END:VCALENDAR
